The Impact of Olaparib Dose Reduction and Treatment Interruption on Treatment Outcome in Platinum-Sensitive Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
Ann. Oncol 2022 Feb 24;[EPub Ahead of Print], KE Francis, SI Kim, M Friedlander, V Gebski, IR Coquard, A Clamp, RT Penson, A Oza, T Perri, T Huzarski, C Martin-Lorente, SC Cecere, N Colombo, B Ataseven, K Fujiwara, G Sonke, I Vergote, E Pujade-Lauraine, JW Kim, CK LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.